SCHEMBL24933335

SCHEMBL24933335

NC(=O)c1cc(-c2ccc(OC(F)F)cc2)c(C(F)(F)F)[nH]c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 7/20 0.44
GRM2 Q14416 1/20 0.43
KDR P35968 1/20 0.38
HSD17B1 P14061 6/20 0.38
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
HTT P42858 2/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HPGD P15428 1/20 0.35
SCN8A Q9UQD0 2/20 0.35
SCN10A Q9Y5Y9 2/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
DRD1 P21728 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24932964 0.89 PARP10 (0.43) HSD17B2HSD17B1MAPTALDH1A1
SCHEMBL24933053 0.85 KDM4E (0.44) HSD17B2HSD17B1MAPTSMN1; SMN2ALDH1A1
SCHEMBL24933256 0.83 PDK2 (0.43) HSD17B2HSD17B1
SCHEMBL24933333 0.83 GSTP1 (0.44) HSD17B2HSD17B1
SCHEMBL24933312 0.82 BTK (0.42) HSD17B2GRM2KDRHSD17B1MEN1
SCHEMBL24933605 0.82 HSD17B2 (0.41) HSD17B2HSD17B1
SCHEMBL30240708 0.81 HSD17B2 (0.42) HSD17B2HSD17B1
SCHEMBL29203326 0.81 HSD17B2 (0.42) HSD17B2HSD17B1
SCHEMBL24933339 0.81 HSD17B1 (0.41) HSD17B2HSD17B1
SCHEMBL24933359 0.81 HSD17B2 (0.50) HSD17B2HSD17B1HPGDALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed